Assessment of Malaria Prevalence and Evaluation of Therapeutic Efficacy of Artemether/Lumefantrine (Coartem®) against Uncomplicated Falciparum Malaria in Wondogenet Woreda, SNNPR, Ethiopia
Ключевые слова:
PharmacologyАннотация
AbstractThe study was conducted to assess malaria prevalence and to evaluate therapeutic efficacy of Coartem® for the treatment of uncomplicated falciparum malaria in Wondogenet Woreda, Sidama Zone, Ethiopia. Since the spread of Plasmodium falciparum, parasite resistance to almost all antimalarial monotherapies is a serious impediment to malaria control. Artemether-lumefantrine (Coartem®) therapy has been in use as the first-line treatment for uncomplicated falciparum malaria since 2004 in Ethiopia. The study was designed according to WHO, 2003 study protocol. The study outcomes were classified into early treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF) and adequate clinical and parasitological response (ACPR). The five-year retrospective data showed an initial decline in malaria prevalence. However, an increasing buildup of cases was observed in 2009. Primary study was also conducted on ninety-nine P. falciparum mono-infected consenting patients who were enrolled in the 28-day in vivo Coartem® treatment followup study. Based on this, the overall cure rate for Coartem® was 98.9% (PCR uncorrected). The study also demonstrated 4.3% Plasmodium vivax and 2.2% P. falciparum/P. vivax co-infections at the end of followup period. There is slight difference with age groups. Following Coartem® treatment, fever was cleared rapidly on days 1 and 2 and parasite clearance was high on days 1 and 3. Therefore, the study showed a high therapeutic efficacy of Coartem® for the treatment of uncomplicated falciparum malaria in Wondogenet Woreda. Keywords: Coartem®, Wondogenet Woreda, cure rate, malaria, parasitemia Cite this Article Esmael B. Assessment of malaria prevalence and evaluation of therapeutic efficacy of artemether/aumefantrine (Coartem®) against uncomplicated falciparum malaria in Wondogenet Woreda, SNNPR, Ethiopia. Research & Reviews: A Journal of Pharmaceutical Science. 2015; 5(2): 26–34p.
Дополнительные файлы
Опубликован
Выпуск
Раздел
Лицензия
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
· I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
· I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
· I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
· I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
_______________
We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
